← Olin overview

Olin vs Dow: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Olin Corporation (OLN)

Q3 2026
▲2▼2

Olin's Huntsman merger advances amid weak demand and a Q2 loss

  • Huntsman merger clears key hurdles Olin's all-stock merger with Huntsman won shareholder approval and passed U.S. antitrust review. The deal targets $300–400 million in cost savings and could add $8–11 per share, though integration risks remain.

    This is the biggest new corporate event that could reshape Olin and lift its value.

  • Weak chemicals demand causes surprise Q2 loss Soft demand for chemicals led to an unexpected second-quarter loss, sending the stock down 16% in one day. The company also gave weak third-quarter profit guidance of $160–200 million.

    This was the main negative shock that drove the stock lower during the period.

  • Epoxy and Winchester sales lift profit Strong sales in Epoxy and Winchester businesses helped adjusted EBITDA rise 8.6% to $191.3 million. A tightening chlor-alkali market could also benefit Olin over the long term.

    These bright spots show parts of the business are performing well despite overall weakness.

  • Analyst downgrade and plant disruption Citi cut its price target to $17, pointing to broad weakness in the chemicals sector. A disruption at Olin's Freeport plant added to operational concerns.

    These events reinforced negative sentiment and highlighted ongoing challenges.

August 2026
▲2▼2

Olin's Huntsman merger advances, but weak chemicals demand and losses weigh

  • Weak Q2 results and soft Q3 guidance Olin posted a wider second-quarter loss of $13.3 million as sales slipped 0.9% to $1.74 billion, and guided third-quarter EBITDA to $160–200 million, including a roughly $20 million hit from a Freeport plant disruption. Weak profits and guidance pressure the stock.

    This is the core earnings reality that sets the baseline for OLN's price this period.

  • Huntsman merger clears key hurdles Shareholders of both companies approved the all-stock merger on August 25, and the U.S. antitrust waiting period expired in September. The deal would create a larger chemicals platform with $300 million in planned cost savings, a major potential boost for Olin.

    The merger is the biggest company-specific catalyst driving OLN's outlook and valuation.

  • Epoxy and Winchester strength offset chlor alkali weakness Epoxy sales jumped 27.4% and Winchester ammunition sales rose 11.8%, lifting adjusted EBITDA 8.6% to $191.3 million and beating revenue expectations. These growing businesses are helping cushion the decline in the larger chlor alkali and vinyls segment.

    It shows which parts of Olin are actually growing and supporting profits despite overall weakness.

  • Citi cuts price target on weak chemical demand Citi kept a Neutral/High Risk rating on Olin and lowered its price target to $17 from $19, citing weak demand that is limiting gains from higher oil and feedstock costs. It also cut targets across many North American chemical peers, signaling broad sector pressure.

    This is the latest analyst view showing demand headwinds that could keep OLN's stock under pressure.

Latest
▲2▼2

Olin's Huntsman merger advances, but weak chemicals demand and losses weigh

  • Weak Q2 results and soft Q3 guidance Olin posted a wider second-quarter loss of $13.3 million as sales slipped 0.9% to $1.74 billion, and guided third-quarter EBITDA to $160–200 million, including a roughly $20 million hit from a Freeport plant disruption. Weak profits and guidance pressure the stock.

    This is the core earnings reality that sets the baseline for OLN's price this period.

  • Huntsman merger clears key hurdles Shareholders of both companies approved the all-stock merger on August 25, and the U.S. antitrust waiting period expired in September. The deal would create a larger chemicals platform with $300 million in planned cost savings, a major potential boost for Olin.

    The merger is the biggest company-specific catalyst driving OLN's outlook and valuation.

  • Epoxy and Winchester strength offset chlor alkali weakness Epoxy sales jumped 27.4% and Winchester ammunition sales rose 11.8%, lifting adjusted EBITDA 8.6% to $191.3 million and beating revenue expectations. These growing businesses are helping cushion the decline in the larger chlor alkali and vinyls segment.

    It shows which parts of Olin are actually growing and supporting profits despite overall weakness.

  • Citi cuts price target on weak chemical demand Citi kept a Neutral/High Risk rating on Olin and lowered its price target to $17 from $19, citing weak demand that is limiting gains from higher oil and feedstock costs. It also cut targets across many North American chemical peers, signaling broad sector pressure.

    This is the latest analyst view showing demand headwinds that could keep OLN's stock under pressure.

July 2026
▲2▼1

Olin's merger advances, but weak chemicals demand and a surprise loss weigh on the stock

  • Olin-Huntsman merger approved by shareholders Shareholders overwhelmingly approved the all-stock merger with Huntsman, creating a $12.5 billion chemicals company. The deal promises over $400 million in cost savings, which could boost future profits and support the stock. It is expected to close in the first half of 2027, pending regulatory approval.

    This is the latest major step in the merger and directly affects OLN's future value.

  • Surprise Q2 loss and 16% stock drop Olin reported a surprise loss of $0.12 per share, missing expectations for a profit, and revenue fell short. The stock dropped about 16% in one day. Weak chlor alkali sales and merger-related costs drove the loss, showing the company's core business is struggling.

    This is a new negative event that directly caused a sharp price decline and reflects fundamental weakness.

  • Chlor-alkali market tightening could lift Olin Hotchkis & Wiley sees North American chlor-alkali supply and demand tightening over the next five-plus years, which could raise prices and volumes. As the region's swing producer, Olin could benefit more than peers. This long-term trend offers a potential recovery path.

    This is a new analyst view on a key market driver that could improve Olin's future earnings.

  • Merger synergies valued, but integration costs and risks remain UBS estimates the merger's cost savings could add $8–$11 per share in value, mainly from procurement, operations, and overhead cuts. However, the deal also brings $10.6 million in acquisition costs and execution risk, and it does not expand into new markets, so the benefit depends on successful integration.

    This explains the financial rationale and potential value of the merger, a key driver for OLN.

▲2▼1

Olin's merger advances, but weak chemicals demand and a surprise loss weigh on the stock

  • Olin-Huntsman merger approved by shareholders Shareholders overwhelmingly approved the all-stock merger with Huntsman, creating a $12.5 billion chemicals company. The deal promises over $400 million in cost savings, which could boost future profits and support the stock. It is expected to close in the first half of 2027, pending regulatory approval.

    This is the latest major step in the merger and directly affects OLN's future value.

  • Surprise Q2 loss and 16% stock drop Olin reported a surprise loss of $0.12 per share, missing expectations for a profit, and revenue fell short. The stock dropped about 16% in one day. Weak chlor alkali sales and merger-related costs drove the loss, showing the company's core business is struggling.

    This is a new negative event that directly caused a sharp price decline and reflects fundamental weakness.

  • Chlor-alkali market tightening could lift Olin Hotchkis & Wiley sees North American chlor-alkali supply and demand tightening over the next five-plus years, which could raise prices and volumes. As the region's swing producer, Olin could benefit more than peers. This long-term trend offers a potential recovery path.

    This is a new analyst view on a key market driver that could improve Olin's future earnings.

  • Merger synergies valued, but integration costs and risks remain UBS estimates the merger's cost savings could add $8–$11 per share in value, mainly from procurement, operations, and overhead cuts. However, the deal also brings $10.6 million in acquisition costs and execution risk, and it does not expand into new markets, so the benefit depends on successful integration.

    This explains the financial rationale and potential value of the merger, a key driver for OLN.

Dow Inc (DOW)

Q3 2026
▼3

Dow Falls on Tariffs, Weak Polyethylene, and Downgrades

  • Canada tariffs raise export costs Canada's retaliatory tariffs are increasing Dow's export costs, making its products less competitive and pressuring profit margins. This adds a new trade-related headwind to an already difficult commodity environment.

    New tariff development directly hurts Dow's cost structure and pricing power.

  • Q3 EBITDA guidance cut on weak demand Dow lowered its third-quarter EBITDA guidance to $1.5–1.6 billion, citing weak polyethylene prices and soft construction and auto demand. This signals that core end markets remain sluggish and earnings recovery is delayed.

    Guidance cut is a fresh negative signal about current profitability.

  • Citi downgrade and price target cut Citi downgraded Dow to Neutral and slashed its price target to $30, also cutting 2027 earnings estimates. This reflects growing analyst skepticism about Dow's near-term earnings power and valuation.

    New analyst downgrade directly lowers market expectations for the stock.

  • Debt paydown, dividend halved, Sadara stake sale weighed Dow is prioritizing debt reduction over buybacks and preserving its halved $0.35 dividend. It is also considering selling its Sadara stake for cash, though that would forfeit future recovery upside. Cost cuts and working-capital release provide some offset.

    New capital allocation decisions and potential asset sale affect financial flexibility and shareholder returns.

August 2026
▼3

Dow Falls on Tariffs, Weak Polyethylene, and Downgrades

  • Canada tariffs raise export costs Canada's retaliatory tariffs are increasing Dow's export costs, making its products less competitive and pressuring profit margins. This adds a new trade-related headwind to an already difficult commodity environment.

    New tariff development directly hurts Dow's cost structure and pricing power.

  • Q3 EBITDA guidance cut on weak demand Dow lowered its third-quarter EBITDA guidance to $1.5–1.6 billion, citing weak polyethylene prices and soft construction and auto demand. This signals that core end markets remain sluggish and earnings recovery is delayed.

    Guidance cut is a fresh negative signal about current profitability.

  • Citi downgrade and price target cut Citi downgraded Dow to Neutral and slashed its price target to $30, also cutting 2027 earnings estimates. This reflects growing analyst skepticism about Dow's near-term earnings power and valuation.

    New analyst downgrade directly lowers market expectations for the stock.

  • Debt paydown, dividend halved, Sadara stake sale weighed Dow is prioritizing debt reduction over buybacks and preserving its halved $0.35 dividend. It is also considering selling its Sadara stake for cash, though that would forfeit future recovery upside. Cost cuts and working-capital release provide some offset.

    New capital allocation decisions and potential asset sale affect financial flexibility and shareholder returns.

Latest
▼2▲1

Dow's recovery hopes fade as analysts cut estimates on weak demand

  • Citi downgrades Dow, slashes price target and 2027 profit forecast Citi cut Dow to Neutral from Buy, lowered its price target to $30 from $35, and reduced its 2027 earnings estimate to $1.21 from $1.83. The analyst said weak demand means even $100 oil won't lift polyethylene prices much, so Dow's profit recovery looks smaller and further away.

    This is the most recent and most concrete negative signal, directly cutting the earnings and price outlook that drive DOW's valuation.

  • Analysts trim Dow estimates ahead of October 22 earnings Ahead of Dow's October 22 earnings report, analysts lowered their profit estimates over the past month, and the stock fell 1% to $27.61, down 8.62% in a month. Lower expectations mean even a decent quarter may not be enough to lift the shares.

    Shows the market's expectations are falling into the key earnings event, a direct drag on DOW's price.

  • Univar expands distribution of Dow's SupraCare products across US and Canada Univar widened its agreement to distribute Dow's SupraCare polymers and specialty additives in the US and Canada, reaching more homecare and industrial cleaning customers. This is a real but modest boost to Dow's sales reach, though it doesn't fix the bigger problem of weak overall chemical demand.

    A concrete new demand-side positive for Dow, but small relative to the demand and pricing headwinds.

  • Dow screens as undervalued, but a peer looks cheaper One analysis said Dow is undervalued, worth about $38 a share based on cash flow, while another preferred LyondellBasell because it's cheaper and lost less money. The bull case rests on Dow's low price, but weak demand and high costs keep the discount in place.

    Captures the valuation debate that frames whether DOW is a bargain or a value trap, a key part of the big picture.

▼2

Dow cuts outlook, faces Canada tariffs, weighs Sadara sale

  • Canada tariffs hit Dow exports Canada's retaliatory tariffs on U.S. goods took effect September 8, hitting plastics and chemicals that include Dow products. This makes Dow's exports to Canada more expensive, likely reducing sales and pressuring profit.

    New trade barrier directly affecting Dow's sales and pricing power.

  • Dow weighs selling Sadara stake Dow is reportedly considering selling its 35% stake in the $20 billion Sadara joint venture with Saudi Aramco. A sale could bring cash but forfeit future recovery upside, and the headline $20 billion is not the current value of Dow's stake.

    Portfolio move with major cash and strategic implications for Dow's balance sheet.

  • Dow trims Q3 EBITDA outlook Dow cut its third-quarter EBITDA forecast to $1.5–1.6 billion, citing weaker polyethylene pricing in the Americas and soft construction and automotive demand. This signals near-term earnings pressure, though cost cuts and working-capital release offer some offset.

    Direct reduction in expected earnings, a key driver of stock value.

  • Debt paydown prioritized over buybacks Dow will use excess cash to reduce debt and does not expect share buybacks in 2026, keeping the $0.35 dividend as the main shareholder return. This strengthens the balance sheet but removes a potential stock support, and the dividend is half its former level.

    Capital allocation shift affects shareholder returns and financial risk.

Q2 2026
▼3▲1

Dow's rally fades as weak polyethylene prices and Alberta costs overshadow growth bets

  • RBC downgrade and price target cut RBC downgraded Dow to Sector Perform and slashed its price target to $28 from $51, warning that recent polyethylene price gains will fade and the Alberta project will strain cash flow. This directly lowers the market's expected value for Dow shares.

    This is the single most direct negative driver of the period, resetting analyst expectations and the stock's perceived worth.

  • Polyethylene oversupply and weak pricing Analysts cut Dow's outlook because polyethylene prices are softening and the market is oversupplied, threatening cash flow and earnings recovery. Dow's commodity business remains under pressure, and the stock fell 8% as these concerns overshadowed positive news.

    This is the core fundamental problem weighing on Dow's earnings and investor confidence, explaining why the stock dropped despite other positive announcements.

  • Chlorpyrifos lawsuit over Parkinson's link Dow faces a lawsuit alleging its insecticide chlorpyrifos is linked to Parkinson's disease, raising the risk of costly litigation, higher insurance premiums, and product restrictions. Until the total legal exposure is clear, this uncertainty weighs on investor sentiment.

    This is a new legal and reputational risk that could lead to material costs and product restrictions, directly affecting Dow's future profitability.

  • Silicone and low-carbon growth investments Dow announced a $100 million investment to expand silicone production for electronics and thermal management, and a distribution deal for its Decarbia low-carbon products. These moves target higher-value, growing markets, but near-term they do little to offset weak commodity pricing.

    These are the main positive strategic actions this period, showing Dow's effort to shift toward specialty and sustainable products, though their impact is longer-term.

June 2026
▼3▲1

Dow's rally fades as weak polyethylene prices and Alberta costs overshadow growth bets

  • RBC downgrade and price target cut RBC downgraded Dow to Sector Perform and slashed its price target to $28 from $51, warning that recent polyethylene price gains will fade and the Alberta project will strain cash flow. This directly lowers the market's expected value for Dow shares.

    This is the single most direct negative driver of the period, resetting analyst expectations and the stock's perceived worth.

  • Polyethylene oversupply and weak pricing Analysts cut Dow's outlook because polyethylene prices are softening and the market is oversupplied, threatening cash flow and earnings recovery. Dow's commodity business remains under pressure, and the stock fell 8% as these concerns overshadowed positive news.

    This is the core fundamental problem weighing on Dow's earnings and investor confidence, explaining why the stock dropped despite other positive announcements.

  • Chlorpyrifos lawsuit over Parkinson's link Dow faces a lawsuit alleging its insecticide chlorpyrifos is linked to Parkinson's disease, raising the risk of costly litigation, higher insurance premiums, and product restrictions. Until the total legal exposure is clear, this uncertainty weighs on investor sentiment.

    This is a new legal and reputational risk that could lead to material costs and product restrictions, directly affecting Dow's future profitability.

  • Silicone and low-carbon growth investments Dow announced a $100 million investment to expand silicone production for electronics and thermal management, and a distribution deal for its Decarbia low-carbon products. These moves target higher-value, growing markets, but near-term they do little to offset weak commodity pricing.

    These are the main positive strategic actions this period, showing Dow's effort to shift toward specialty and sustainable products, though their impact is longer-term.

▼3▲1

Dow's rally fades as weak polyethylene prices and Alberta costs overshadow growth bets

  • RBC downgrade and price target cut RBC downgraded Dow to Sector Perform and slashed its price target to $28 from $51, warning that recent polyethylene price gains will fade and the Alberta project will strain cash flow. This directly lowers the market's expected value for Dow shares.

    This is the single most direct negative driver of the period, resetting analyst expectations and the stock's perceived worth.

  • Polyethylene oversupply and weak pricing Analysts cut Dow's outlook because polyethylene prices are softening and the market is oversupplied, threatening cash flow and earnings recovery. Dow's commodity business remains under pressure, and the stock fell 8% as these concerns overshadowed positive news.

    This is the core fundamental problem weighing on Dow's earnings and investor confidence, explaining why the stock dropped despite other positive announcements.

  • Chlorpyrifos lawsuit over Parkinson's link Dow faces a lawsuit alleging its insecticide chlorpyrifos is linked to Parkinson's disease, raising the risk of costly litigation, higher insurance premiums, and product restrictions. Until the total legal exposure is clear, this uncertainty weighs on investor sentiment.

    This is a new legal and reputational risk that could lead to material costs and product restrictions, directly affecting Dow's future profitability.

  • Silicone and low-carbon growth investments Dow announced a $100 million investment to expand silicone production for electronics and thermal management, and a distribution deal for its Decarbia low-carbon products. These moves target higher-value, growing markets, but near-term they do little to offset weak commodity pricing.

    These are the main positive strategic actions this period, showing Dow's effort to shift toward specialty and sustainable products, though their impact is longer-term.